These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31356559)

  • 41. Safety of long-term PPI therapy.
    Reimer C
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):443-54. PubMed ID: 23998981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study.
    de Bortoli N; Guidi G; Martinucci I; Savarino E; Imam H; Bertani L; Russo S; Franchi R; Macchia L; Furnari M; Ceccarelli L; Savarino V; Marchi S
    Dis Esophagus; 2016; 29(2):197-204. PubMed ID: 25516110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US.
    Rane PP; Guha S; Chatterjee S; Aparasu RR
    Res Social Adm Pharm; 2017; 13(2):358-363. PubMed ID: 27033427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastroesophageal reflux guidelines: the European experience.
    McCracken M
    J Pediatr Gastroenterol Nutr; 2014 Apr; 58(4):395-6. PubMed ID: 24795980
    [No Abstract]   [Full Text] [Related]  

  • 46. [Evidence-Based Indication for Proton Pump Inhibitors - a Group Practice Perspective].
    Gerber T; Zeller A
    Praxis (Bern 1994); 2021; 110(4):193-200. PubMed ID: 33726514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prescription of PPI in Germany: too often, too long, too much?].
    Gross M; Labenz J
    MMW Fortschr Med; 2018 Feb; 160(2):37-40. PubMed ID: 29417513
    [No Abstract]   [Full Text] [Related]  

  • 48. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton pump inhibitor prescribing patterns in the UK: a primary care database study.
    Othman F; Card TR; Crooks CJ
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1079-87. PubMed ID: 27255671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is there a role for proton pump inhibitor prophylaxis in haematology patients?
    Leitinger E; Hui L; Grigg A
    Intern Med J; 2019 Jun; 49(6):694-701. PubMed ID: 30719802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Yadlapati R; DeLay K
    Med Clin North Am; 2019 Jan; 103(1):15-27. PubMed ID: 30466671
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alternative therapeutic approaches to chronic proton pump inhibitor treatment.
    Fass R
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):338-45; quiz e39-40. PubMed ID: 22178462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Refractory gastroesophageal reflux disease (GERD) and PPI safety].
    Huerta-Iga FM
    Rev Gastroenterol Mex; 2013 Aug; 78 Suppl 1():1-3. PubMed ID: 24041041
    [No Abstract]   [Full Text] [Related]  

  • 54. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?
    Heidelbaugh JJ; Metz DC; Yang YX
    Int J Clin Pract; 2012 Jun; 66(6):582-91. PubMed ID: 22607510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unexpected consequences of proton pump inhibitor use.
    Altman KW; Radosevich JA
    Otolaryngol Head Neck Surg; 2009 Nov; 141(5):564-6. PubMed ID: 19861191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors.
    Raghunath AS; Hungin AP; Mason J; Jackson W
    Aliment Pharmacol Ther; 2009 Feb; 29(4):431-9. PubMed ID: 19035981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risks versus benefits of long-term proton pump inhibitor therapy in the elderly.
    Schuler A
    Geriatr Nurs; 2007; 28(4):225-9. PubMed ID: 17936957
    [No Abstract]   [Full Text] [Related]  

  • 60. We Are Using Too Many PPIs, and We Need to Stop: A European Perspective.
    Lanas A
    Am J Gastroenterol; 2016 Aug; 111(8):1085-6. PubMed ID: 27166129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.